Drug Discovery World
OCTOBER 25, 2022
Recombinant production is a field in which Sino Biological has extensive expertise – the company boasts several platforms to use recombinant DNA technology for the manufacturing of a variety of proteins and antibodies to expedite the process of novel drug identification and validation, for example. .
Drug Discovery World
OCTOBER 25, 2022
Recombinant production is a field in which Sino Biological has extensive expertise – the company boasts several platforms to use recombinant DNA technology for the manufacturing of a variety of proteins and antibodies to expedite the process of novel drug identification and validation, for example. .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
JANUARY 21, 2024
With fourteen approved drugs and several drug candidates being evaluated under different stages of development, antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics. In this context, the role of the linker molecule and the conjugation technology used is pivotal.
Pharmaceutical Technology
FEBRUARY 24, 2023
According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Amivantamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Pharma Packaging Solutions
JUNE 30, 2023
Biopharmaceuticals, also called biologics, are drug products that are manufactured using biological sources. Whole blood, organ and tissue transplants, breast milk, antibodies for passive immunity, fecal microbiota, human reproductive cells, and stem-cell therapy are all examples of this type of biologic.
Cloudbyz
MARCH 6, 2024
Traditionally, pharmaceutical therapies have primarily consisted of small molecule drugs, commonly known as pills. This shift signifies not just a change in the way drugs are manufactured and administered, but also a fundamental transformation in the approach to treating diseases at their root cause.
The Pharma Data
JULY 11, 2021
TAKHZYRO is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein activity. TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. No dedicated drug-drug interaction studies have been conducted. All antibody titres were low.
Expert insights. Personalized for you.
52 
Let's personalize your content